OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	166
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	150
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	144
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	124
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	116
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	105
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	92
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	69
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	67
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	67
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	66
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	64
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	64
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	63
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	59
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	59
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	55
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	55
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	54
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	51
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	48
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	48
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	46
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	45
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	45

HIV associated lymphoma: latest updates from 2023 ASH annual meeting	45
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	44
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	43
Breast cancer heterogeneity and its implication in personalized precision therapy	41
Role of m6A writers, erasers and readers in cancer	40
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	39
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	39
Three-dimensional chromatin landscapes in MLLr AML	38
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	37
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	36
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	36
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	36
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	35
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	34
TCR engineered T cells for solid tumor immunotherapy	34
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	34
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	33
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	32
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	30
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	30
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	30
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	29
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	29
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	29
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	28
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	27
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	27
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	26
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	26
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	26
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	26
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	26
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	26
Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model	26
Recent advances and future perspectives in the therapeutics of prostate cancer	25
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	25
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	25
Immunotherapy in breast cancer: current landscape and emerging trends	25
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	25
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	25
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	24
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	24
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	23
New exploration of KRASG12D inhibitors and the mechanisms of resistance	23
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	23
Antibody-drug conjugates in breast cancer: current evidence and future directions	23
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	22
The clinical impact of IKZF1 mutation in acute myeloid leukemia	22
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	22
Versatile function of NF-ĸB in inflammation and cancer	22

The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	21
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	21
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	21
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	21
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	21
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	20
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	20
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	20
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	19
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	19
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	19
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	18
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	18
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	18
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	18
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	18
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	17
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	17
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	17
The roles of tissue resident macrophages in health and cancer	17
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	17
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	17
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	17
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	17
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	16
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	16
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	16
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	16
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	16
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	16
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	16
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	16
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	16
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	16
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	16
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	15
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	15
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	15
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	15
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	15
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	15
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	15